Sugi Predict

Sugi Predict / Targets / PDE1B

PDE1B

Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B · Q01064 · PDE1B on Sugi Atlas →

52,674 patent compounds predicted against PDE1B, 29,294 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL285263 SCHEMBL285263 0.72 16/20
SCHEMBL285264 SCHEMBL285264 0.72 16/20
SCHEMBL407938 SCHEMBL407938 0.72 16/20
SCHEMBL155132 SCHEMBL155132 0.50 14/20
SCHEMBL291618 SCHEMBL291618 0.53 12/20
SCHEMBL299992 SCHEMBL299992 0.59 11/20
SCHEMBL298932 SCHEMBL298932 0.52 11/20
SCHEMBL299743 SCHEMBL299743 0.62 10/20
SCHEMBL298595 SCHEMBL298595 0.62 10/20
SCHEMBL298757 SCHEMBL298757 0.62 10/20
SCHEMBL299367 SCHEMBL299367 0.59 10/20
SCHEMBL299935 SCHEMBL299935 0.55 10/20
SCHEMBL299164 SCHEMBL299164 0.52 10/20
SCHEMBL299194 SCHEMBL299194 0.52 10/20
SCHEMBL299001 SCHEMBL299001 0.51 10/20
SCHEMBL299557 SCHEMBL299557 0.51 10/20
SCHEMBL299352 SCHEMBL299352 0.50 10/20
SCHEMBL299383 SCHEMBL299383 0.50 10/20
SCHEMBL5537 SCHEMBL5537 1.00 9/20
Idoxifene Idoxifene (SCHEMBL19216) 1.00 9/20

Clinical trials — most relevant to PDE1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm PHASE3WITHDRAWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial PHASE2COMPLETED
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) PHASE2RECRUITING
A Trial of Metformin in Individuals With Fragile X Syndrome (Met) PHASE2COMPLETED
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) PHASE1RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. nanUNKNOWN
Endurance Performance at Altitude nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE1B binder may also engage these)

ProteinNameSimilarity
Q01066 — 1.000 Q01066 →
Q01061 — 0.999 Q01061 →
Q64395 — 0.997 Q64395 →
Q01065 — 0.997 Q01065 →
Q61481 — 0.992 Q61481 →
P14100 — 0.991 P14100 →
PDE1A Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A 0.988 landscape →
Q64338 — 0.969 Q64338 →
PDE1C Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C 0.967 landscape →
PDE7A High affinity 3',5'-cyclic-AMP phosphodiesterase 7A 0.960 landscape →
Q63421 — 0.960 Q63421 →
O08593 — 0.958 O08593 →
P70453 — 0.955 P70453 →
A6NI28 — 0.955 A6NI28 →
A7MBL8 — 0.954 A7MBL8 →
Q9QXQ1 — 0.953 Q9QXQ1 →
O70566 — 0.952 O70566 →
E9Q4Z2 — 0.951 E9Q4Z2 →
PDE7B 3',5'-cyclic-AMP phosphodiesterase 7B 0.951 landscape →
Q9NSV4 — 0.951 Q9NSV4 →
B5DFQ4 — 0.951 B5DFQ4 →
Q5CD77 — 0.951 Q5CD77 →
MTMR1 Phosphatidylinositol-3-phosphate phosphatase MTMR1 0.950 landscape →
Q7YQL6 — 0.950 Q7YQL6 →
Q8BWW9 — 0.950 Q8BWW9 →
O60879 — 0.950 O60879 →
Q5U4T3 — 0.949 Q5U4T3 →
Q8BPM2 — 0.949 Q8BPM2 →
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 0.948 landscape →
Q6DIX1 — 0.948 Q6DIX1 →